BioAge Labs to Present at Upcoming Investor Conferences

Rhea-AI Summary

BioAge Labs (NASDAQ: BIOA), a clinical-stage biotech company focused on developing therapeutics for metabolic diseases through aging biology, has announced its participation in two major upcoming investor conferences. The company's leadership, including CEO and co-founder Dr. Kristen Fortney and CFO Dr. Dov Goldstein, will attend:

• The Jefferies Global Healthcare Conference in New York (June 3-5, 2025) for one-on-one meetings

• The Goldman Sachs 46th Annual Global Healthcare Conference in Miami (June 9-11, 2025), featuring a fireside chat on June 9 at 3:20 PM EDT and one-on-one meetings. A webcast will be available and archived for 30 days on the company's investor relations website.

News Market Reaction

+0.76%

1 alert

+0.76% News Effect

On the day this news was published, BIOA gained 0.76%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

EMERYVILLE, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:

• Jefferies Global Healthcare Conference (New York, June 3–5, 2025): Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, will participate in one-on-one meetings.

• Goldman Sachs 46th Annual Global Healthcare Conference (Miami, June 9–11, 2025): Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, are scheduled to participate in a fireside chat on Monday, June 9, 2025 at 3:20–3:55 PM EDT, and will participate in one-on-one meetings. To access the live webcast of the presentation, register here.

Replays of the webcasts will be available in the investor section of the company's website at https://ir.bioagelabs.com/, and will be archived for 30 days following the presentations.

About BioAge Labs, Inc.

BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company’s pipeline includes novel, orally available, brain-penetrant small-molecule NLRP3 inhibitors to treat metabolic diseases and conditions driven by neuroinflammation, as well as novel APJ agonists for metabolic disorders. BioAge’s additional preclinical programs, which leverage insights from the Company’s proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.

Contacts
PR: Chris Patil, media@bioagelabs.com
IR: Dov Goldstein, ir@bioagelabs.com
Partnering: partnering@bioagelabs.com
Web: https://bioagelabs.com

FAQ

When is BioAge Labs (BIOA) presenting at the Goldman Sachs Healthcare Conference 2025?

BioAge Labs is scheduled for a fireside chat presentation on Monday, June 9, 2025, from 3:20 to 3:55 PM EDT at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami.

Which executives from BioAge Labs (BIOA) will attend the upcoming investor conferences?

CEO and co-founder Dr. Kristen Fortney and CFO Dr. Dov Goldstein will represent BioAge Labs at both the Jefferies and Goldman Sachs healthcare conferences.

Where can I watch BioAge Labs' (BIOA) Goldman Sachs conference presentation?

The presentation webcast will be available through registration and archived for 30 days on BioAge's investor relations website at https://ir.bioagelabs.com/.

What type of company is BioAge Labs (BIOA)?

BioAge Labs is a clinical-stage biotechnology company that develops therapeutic product candidates for metabolic diseases by targeting the biology of human aging.